<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Paclitaxel</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01229</strong>&#160; (APRD00259, DB05261, DB05927)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel.<br>
When it was developed commercially by Bristol-Myers Squibb (<span class="caps">BMS</span>), the generic name was changed to paclitaxel and the <span class="caps">BMS</span> compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01229/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01229/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01229.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01229.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01229.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01229.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01229.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01229">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Taxol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Taxol A</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Abraxane</td><td>Abraxis Bioscience</td></tr><tr><td>Onxol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Paxceed</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Paxene</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Taxol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antineoplastic-agents-phytogenic">Antineoplastic Agents, Phytogenic</a></li>
<li><a href="/mesh/tubulin-modulators">Tubulin Modulators</a></li></ul></td></tr><tr><th>CAS number</th><td>33069-62-4</td></tr><tr><th>Weight</th><td>Average: 853.9061<br>Monoisotopic: 853.330955345</td></tr><tr><th>Chemical Formula</th><td>C<sub>47</sub>H<sub>51</sub>NO<sub>14</sub></td></tr><tr><th>InChI Key</th><td>RCINICONZNJXQF-MZXODVADSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Prenol Lipids</td></tr><tr><th>Subclass</th><td>Diterpenes</td></tr><tr><th>Direct parent</th><td>Taxanes and 11(15-&gt;1)Abeotaxanes</td></tr><tr><th>Alternative parents</th><td>Germacrane Sesquiterpenes; Phenylpyruvic Acid Derivatives; Beta Amino Acids and Derivatives; Benzoic Acid Esters; Phenylpropylamines; Benzamides; Benzylethers; Benzoyl Derivatives; Cyclohexanols; Dicarboxylic Acids and Derivatives; Tertiary Alcohols; Ketones; Cyclic Alcohols and Derivatives; Oxetanes; Carboxylic Acid Esters; Secondary Carboxylic Acid Amides; Dialkyl Ethers; Carboxylic Acids; Enolates; Polyamines; Aldehydes</td></tr><tr><th>Substituents</th><td>germacrane sesquiterpene; phenylpyruvate; beta amino acid or derivative; benzoate ester; phenylpropylamine; benzylether; benzamide; benzoic acid or derivative; benzoyl; cyclohexanol; benzene; dicarboxylic acid derivative; tertiary alcohol; cyclic alcohol; oxetane; carboxylic acid ester; ketone; carboxamide group; secondary alcohol; secondary carboxylic acid amide; polyamine; carboxylic acid; dialkyl ether; carboxylic acid derivative; enolate; ether; amine; carbonyl group; alcohol; organonitrogen compound; aldehyde</td></tr><tr><th>Classification description</th><td>This compound belongs to the taxanes and 11(15-&gt;1)abeotaxanes. These are diterpenes whose structure is based on the taxane or 11(15-&gt;1)abeaotaxane skeleton, which is characterized by a 6-8-6 tricyclic ring system.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane&#174; is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.</td></tr><tr><th>Pharmacodynamics</th><td>Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.</td></tr><tr><th>Mechanism of action</th><td>Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the &#946; subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.</td></tr><tr><th>Absorption</th><td>When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the maximum plasma concentration (Cmax) is 195 ng/mL, while the AUC is 6300 ng&#8226;h/mL. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>227 to 688 L/m^2 [apparent volume of distribution at steady-state, 24 hour infusion]</li>
</ul></td></tr><tr><th>Protein binding</th><td>89%-98% bound to plasma protein. The presence of cimetidine, ranitidine, dexamethasone, or diphenhydramine did not affect protein binding of paclitaxel.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. In vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6a-hydrox-ypaclitaxel by the cytochrome P450 isozyme CYP2C8; and to two minor metabolites, 3&#8217;-p-hydroxypaclitaxel and 6a, 3&#8217;-p-dihydroxypaclitaxel, by CYP3A4.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Paclitaxel</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00719">3'-p-hydroxypaclitaxel</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/740">Details</a></td></tr><tr><td>Paclitaxel</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00773">6a-hydrox-ypaclitaxel</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/794">Details</a></td></tr><tr><td>Paclitaxel</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00774">6a, 3'-p-dihydroxypaclitaxel</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/795">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>In 5 patients administered a 225 or 250 mg/m2 dose of radiolabeled paclitaxel as a 3-hour infusion, a mean of 71% of the radioactivity was excreted in the feces in 120 hours, and 14% was recovered in the urine.</td></tr><tr><th>Half life</th><td>When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours. </td></tr><tr><th>Clearance</th><td><ul>
	<li>21.7 L/h/m2 [Dose 135 mg/m2, infusion duration 24 h]</li>
	<li>23.8 L/h/m2 [Dose 175 mg/m2, infusion duration 24 h]</li>
	<li>7 L/h/m2 [Dose 135 mg/m2, infusion duration 3 h]</li>
	<li>12.2 L/h/m2 [Dose 175 mg/m2, infusion duration 3 h]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Rat (ipr) LD<sub>50</sub>=32530 &#181;g/kg. Symptoms of overdose include bone marrow suppression, peripheral neurotoxicity, and mucositis. Overdoses in pediatric patients may be associated with acute ethanol toxicity.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Paclitaxel Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.914</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9748</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8345</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5509</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7309</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9349</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.837</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7278</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8937</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9158
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9491
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4391 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9978
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7982
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Abraxis bioscience llc</li>
<li>Accord healthcare inc usa</li>
<li>Actavis totowa llc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Ebewe pharma ges mbh nfg kg</li>
<li>Fresenius kabi oncology plc</li>
<li>Hospira inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Pliva lachema as</li>
<li>Teva parenteral medicines inc</li>
<li>Bristol myers squibb co pharmaceutical research institute</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abraxisbio.com">Abraxis BioScience Inc.</a></li>
<li><a href="http://www.accord-healthcare.com">Accord Healthcare</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://www.ebewe.at">Ebewe Pharma</a></li>
<li><a href="http://www.ethex.com">Ethex Corp.</a></li>
<li><a href="http://www.fresenius-kabi.com">Fresenius Kabi AB</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.intaspharma.com">Intas Pharmaceuticals Ltd.</a></li>
<li>Ivax Pharmaceuticals</li>
<li><a href="http://www.meadjohnson.com">Mead Johnson and Co.</a></li>
<li>Pharmachemie BV</li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Concentrate</td><td>Intravenous</td><td>100 mg/16.7 mL; 30 mg/5 mL; 150 mg/25 mL; 300 mg/50 mL</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>Aprepitant may change levels of the chemotherapy agent, paclitaxel.</td></tr><tr><td><a href="/drugs/DB06626">Axitinib</a></td><td>Avoid combination due to potential for decrease in serum concentration of axitinib.</td></tr><tr><td><a href="/drugs/DB00958">Carboplatin</a></td><td>Platinum derivatives such as carboplatin may enhance the myelosuppressive effect of taxane derivatives such as paclitaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administering the taxane derivative before the platinum derivative seems prudent. </td></tr><tr><td><a href="/drugs/DB00515">Cisplatin</a></td><td>Cisplatin increases the effect and toxicity of paclitaxel</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Avoid combination due to the potential enhancement of agranulocytosis by clozapine. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Avoid combination because it will likely increase the serum concentration of CYP3A4 substrates. </td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Paclitaxel, when used concomitantly with NNRTIs, may experience an increase in serum concentration. It is recommended to monitor for paclitaxel toxicity.</td></tr><tr><td><a href="/drugs/DB00441">Gemcitabine</a></td><td>Paclitaxel increases the effect/toxicity of gemcitabine</td></tr><tr><td><a href="/drugs/DB00108">Natalizumab</a></td><td>Avoid combination due to the increased risk of infection.
</td></tr><tr><td><a href="/drugs/DB06589">Pazopanib</a></td><td>Pazopanib increases exposure of paclitaxel </td></tr><tr><td><a href="/drugs/DB00337">Pimecrolimus</a></td><td>Avoid combination due to the enhancement of adverse effects of immunosuppressants. </td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>Avoid combination due to potential decrease in serum concentration of paclitaxel.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Avoid combination of topical tacrolimus due to the potential enhancement of adverse effects of immunosuppressants.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Paclitaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Paclitaxel if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Paclitaxel. Consider alternate therapy or monitor for changes in Paclitaxel therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Concomitant therapy may also increase Trastuzumab serum concentration and decrease Paclitaxel serum concentrations. Monitor closely for adverse events and therapeutic response.  </td></tr><tr><td><a href="/drugs/DB00385">Valrubicin</a></td><td>The taxane derivative, Paclitaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of paclitaxel by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of paclitaxel if voriconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid echinacea.</li>
<li>Avoid grapefruit and grapefruit juice due to potential increase of paclitaxel. </li></ul></td></tr></tbody></table>